Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Next Previous
X
Search
Trial Profile

A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Revusiran (Primary)
  • Indications Transthyretin-related hereditary amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAVOUR
  • Sponsors Alnylam Pharmaceuticals

    • Most Recent Events

    • 01 May 2020 Results assessing prevalence of mixed phenotype presentation in patients with hereditary transthyretin-mediated amyloidosis with cardiomyopathy, presented at the 72nd Annual Meeting of the American Academy of Neurology.
    • 27 Jul 2017 According to an Alnylam Pharmaceuticals media release, the company will host its 4th annual series of "RNAi Roundtable" webcasts in summer and Fall 2017 and plans to present data from this trial in one of the webcasts (August 9, 2017).
    • 19 May 2017 This trial has been completed in Sweden (End date:2017-03-30) as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top